Last updated: July 31, 2026
Human albumin is a plasma-derived biologic used for volume expansion, hypoalbuminemia-associated conditions, cirrhosis complications, burns, surgery and selected intensive-care applications. The commercial market is growing, driven by rising plasma collection, higher use in liver disease and critical care, and expanded manufacturing capacity. Clinical evidence is strongest for selected cirrhosis indications and weaker for routine albumin use in general intensive care.
The global human albumin market was estimated by commercial research firms at roughly $5 billion to $7 billion in the early 2020s. Published forecasts generally indicate mid-single-digit annual growth through 2030, with projected market values ranging from approximately $8 billion to more than $10 billion depending on geographic scope and product definition. Grifols, CSL Behring, Takeda, China Biologics Products Holdings, Octapharma and domestic Chinese plasma companies are major participants.
What is human albumin and how is it regulated?
Human albumin is a purified plasma protein manufactured from pooled human plasma. It is supplied primarily as 5%, 20% and 25% intravenous solutions.
In the United States, albumin products are biological products regulated by the FDA’s Center for Biologics Evaluation and Research. They are generally approved under biologics licensing applications rather than conventional new drug applications. FDA-approved products include:
| Product |
Company |
Typical concentrations |
Regulatory status |
| Albuminex |
Grifols |
5%, 25% |
FDA-licensed human albumin |
| Albuminar-25 |
CSL Behring |
25% |
FDA-licensed human albumin |
| Albutein |
Grifols |
5%, 20%, 25% |
FDA-licensed human albumin |
| Flexbumin |
Takeda |
5%, 25% |
FDA-licensed human albumin |
| Plasbumin-5 |
Multiple regional suppliers |
5% |
Licensed in selected jurisdictions |
Human albumin is not a small-molecule generic market. Manufacturing depends on qualified plasma supply, validated fractionation, viral clearance, sterile filling and cold-chain distribution. These requirements create higher entry barriers than conventional injectable generics.
What FDA indications are approved for human albumin?
U.S. labeling varies by product, but approved or labeled uses generally include:
- Hypovolemia and hypovolemic shock
- Hypoalbuminemia
- Burns
- Acute respiratory distress syndrome in selected products
- Cardiopulmonary bypass
- Hemolytic disease of the newborn in selected products
- Ovarian hyperstimulation syndrome
- Therapeutic plasma exchange
- Removal of ascites in cirrhosis, depending on product labeling
- Prevention of circulatory dysfunction after large-volume paracentesis
Albumin is administered intravenously. The 5% solution is primarily used for plasma-volume expansion. Concentrations of 20% and 25% are used when clinicians seek oncotic volume with lower infused fluid volume, including after large-volume paracentesis.
What clinical trials have evaluated human albumin?
Clinical development has focused on cirrhosis, spontaneous bacterial peritonitis, hepatorenal syndrome, sepsis, critical illness, cardiac surgery, burns and plasma exchange.
Which albumin trials produced positive results?
The ANSWER trial evaluated long-term albumin administration in patients with uncomplicated decompensated cirrhosis receiving standard medical treatment. Weekly albumin was associated with improved overall survival and fewer complications compared with standard treatment alone. The study was published in The Lancet in 2018 and remains a central basis for interest in long-term albumin treatment in cirrhosis (Caraceni et al., 2018).
The ATTIRE trial evaluated targeted albumin administration in hospitalized patients with decompensated cirrhosis and serum albumin below 30 g/L. The strategy increased serum albumin but did not reduce infection, renal dysfunction or mortality. Serious adverse events were more frequent in the albumin group (China et al., 2021).
Albumin is also established in selected complications of cirrhosis:
- Prevention of post-paracentesis circulatory dysfunction after large-volume paracentesis
- Adjunctive therapy for spontaneous bacterial peritonitis
- Volume support in hepatorenal syndrome, typically with vasoconstrictor therapy
These uses are reflected in major hepatology guidance, although recommendations differ by clinical setting, dose and evidence strength (Biggins et al., 2021; European Association for the Study of the Liver, 2018).
What recent trials have tested albumin in intensive care?
Large critical-care trials have generally not established routine albumin superiority over crystalloids for unselected patients.
The SAFE trial compared 4% albumin with saline in nearly 7,000 intensive-care patients. Overall mortality was similar. A prespecified subgroup analysis suggested possible benefit in severe sepsis, but the study was not designed to establish albumin as a universal standard (Finfer et al., 2004).
The ALBIOS trial studied albumin plus crystalloid versus crystalloid alone in severe sepsis or septic shock. The primary outcome was not significantly improved, although a post hoc subgroup analysis suggested lower mortality in patients with septic shock (Caironi et al., 2014).
The FRISC trial evaluated albumin versus saline in patients with cirrhosis and sepsis-induced hypotension. Albumin improved short-term hemodynamic outcomes, but the study did not establish a broad mortality benefit (Sharma et al., 2021).
The current clinical position is selective use rather than routine administration for all critically ill patients.
What is the status of albumin trials in cirrhosis?
| Study |
Population |
Intervention |
Main result |
| ANSWER |
Outpatients with uncomplicated decompensated cirrhosis |
Long-term albumin plus standard care |
Improved survival and reduced complications |
| ATTIRE |
Hospitalized patients with decompensated cirrhosis |
Targeted albumin to serum albumin threshold |
No improvement in composite clinical outcome |
| CONFIRM |
Hepatorenal syndrome type 1 |
Albumin with terlipressin or placebo |
Supports albumin use with terlipressin; safety and respiratory events require monitoring |
| FRISC |
Cirrhosis with sepsis-induced hypotension |
Albumin versus saline |
Short-term hemodynamic benefit; limited mortality evidence |
| ALBIOS |
Severe sepsis or septic shock |
Albumin plus crystalloids |
No significant overall mortality improvement |
| SAFE |
General ICU population |
4% albumin versus saline |
Similar overall mortality |
The main development opportunity is not a new albumin molecule. It is optimization of dose, duration, patient selection, biomarkers and combination treatment. Long-term outpatient albumin in cirrhosis remains commercially attractive but has not produced uniform results across health systems and trial populations.
When does human albumin lose exclusivity?
Human albumin does not have a single global patent-expiration date. The core product is a naturally occurring human plasma protein, and commercial products have been marketed for decades. Market protection is based primarily on regulatory licenses, plasma supply, manufacturing know-how, facility qualification, trademarks and distribution contracts.
Traditional composition-of-matter patent protection is therefore limited. Relevant intellectual-property protection can cover:
- Plasma fractionation and purification processes
- Viral inactivation and removal
- Stabilizers and excipients
- Container-closure systems
- Filling and packaging
- Recombinant albumin production
- Albumin-based drug delivery systems
- Combination products and specific therapeutic uses
What patents protect human albumin products?
Product-specific patent claims may cover manufacturing and formulation technologies rather than albumin itself. Key patent risk areas include:
- Fractionation technology. Ethanol fractionation, chromatography and filtration processes can be protected through process patents and trade secrets.
- Pathogen safety. Viral inactivation, nanofiltration and prion-reduction methods can create manufacturing barriers.
- High-concentration formulations. Stabilizer systems, pH control, low-volume packaging and shelf-life improvements may be protected.
- Recombinant albumin. Recombinant human serum albumin can be protected by production-cell lines, vectors, purification methods and applications.
- Drug delivery. Albumin-binding technologies and albumin-drug conjugates have separate patent estates.
The practical protection period is often determined by manufacturing capability and regulatory acceptance rather than by a single blocking patent. A new supplier must demonstrate consistent product quality, control of plasma-derived risks and reliable commercial-scale supply.
Is human albumin listed in the Orange Book?
Human albumin products are generally not treated as conventional Orange Book products because they are licensed biological products. The principal regulatory records are FDA biologics-license materials, product labeling and related biologics databases.
The Orange Book is primarily used for approved drug products regulated under the Federal Food, Drug, and Cosmetic Act. For biologics, the relevant competitive framework is the Public Health Service Act, including the abbreviated pathway for biosimilar and interchangeable biological products.
Human albumin is not a typical biosimilar opportunity in the same way as monoclonal antibodies or insulin products. A follow-on manufacturer would need to address product comparability, purity, potency, impurities, viral safety and manufacturing consistency. The absence of a conventional Orange Book listing does not eliminate regulatory or commercial competition.
Are there Paragraph IV challenges for human albumin?
Paragraph IV litigation is not the central competitive mechanism for licensed human albumin products. Paragraph IV certifications apply to patents listed for eligible drug products in the FDA Orange Book. Because human albumin is regulated as a biologic, competitive entry generally proceeds through biologics licensing routes rather than through an abbreviated new drug application supported by a standard Paragraph IV certification.
Potential disputes may instead involve:
- Patent infringement claims against manufacturing processes
- Trade-secret litigation
- Biosimilar or follow-on biologic applications
- Labeling and interchangeability disputes
- Contract manufacturing restrictions
- Plasma-sourcing agreements
- Trademark and unfair-competition claims
No class-wide, patent-driven generic cliff comparable to those affecting major small-molecule drugs defines the human albumin market.
Which companies dominate the human albumin market?
Grifols
Grifols is one of the largest global plasma-derived therapeutics companies and has a major albumin business through products including Albutein and Albuminex. Its competitive position is supported by plasma-collection centers, fractionation capacity, global regulatory licenses and hospital distribution.
CSL Behring
CSL Behring markets Albuminar and has substantial plasma collection and fractionation infrastructure. CSL’s vertically integrated supply chain supports albumin, immunoglobulins and coagulation products.
Takeda
Takeda markets Flexbumin in several markets following its acquisition of Shire. Takeda’s plasma-derived product portfolio includes immunoglobulins and albumin, although its strategic focus has increasingly emphasized specialty medicines and plasma-derived therapies.
China-based manufacturers
China has expanded plasma collection and domestic fractionation capacity. China Biologics Products Holdings, China Resources Boya Bio-pharmaceutical and other regional suppliers participate in albumin and immunoglobulin markets. Domestic supply remains strategically important because China has historically relied on imported albumin while expanding local plasma collection.
Octapharma and regional suppliers
Octapharma and other plasma-product manufacturers compete in Europe, Asia-Pacific, Latin America and selected Middle Eastern markets. Market access varies by national tenders, reimbursement, local manufacturing rules and plasma policy.
How large is the human albumin market?
Commercial market estimates vary because some reports include only human albumin, while others combine albumin with all plasma-derived products. A practical market range is:
| Metric |
Market assessment |
| Estimated global human albumin market, early 2020s |
Approximately $5 billion-$7 billion |
| Expected annual growth through 2030 |
Generally 4%-7% |
| Potential global market by 2030 |
Approximately $8 billion-$10 billion or more |
| Fastest-growth regions |
China, India, Southeast Asia and parts of the Middle East |
| Primary demand channels |
Hospitals, intensive care, hepatology, surgery and plasma exchange |
Growth is supported by:
- Increasing diagnosis of chronic liver disease
- Greater use of albumin after large-volume paracentesis
- Expansion of intensive-care capacity
- Higher plasma collection in the United States and Europe
- Rising albumin consumption in China
- Increased adoption of plasma exchange
- Price increases and supply constraints in selected markets
Demand is constrained by:
- High manufacturing cost
- Dependence on human plasma
- Variable reimbursement
- Clinical disagreement over broad ICU use
- Albumin shortages during periods of reduced plasma collection
- Competition from crystalloids and synthetic or semi-synthetic volume expanders
What is the revenue exposure to albumin?
For major plasma companies, albumin is material but usually less strategically important than immunoglobulin products. Albumin has lower unit economics than some specialty plasma products, but it provides a large-volume revenue base and uses the same plasma-fractionation infrastructure.
The commercial value of albumin is concentrated in:
- Hospital tenders
- Large-volume institutional purchasing
- Long-term supply agreements
- Government procurement
- Emerging-market demand
- Portfolio sales alongside immunoglobulins and coagulation products
Volume growth does not automatically translate into margin expansion. Plasma acquisition costs, donor compensation, testing, labor, energy, sterile manufacturing and freight affect profitability. Albumin prices also vary substantially by concentration, package size, market and tender structure.
How strong is the patent and manufacturing estate for human albumin?
The patent estate is moderate at the product-class level but strong at the manufacturing-platform level.
| Protection category |
Relative strength |
Commercial relevance |
| Native albumin composition |
Low |
No meaningful composition-of-matter exclusivity |
| Plasma collection network |
High |
Difficult and expensive to replicate |
| Fractionation process |
High |
Critical for yield, purity and consistency |
| Viral-clearance validation |
High |
Regulatory barrier and quality differentiator |
| Formulation and packaging |
Moderate |
Can support product differentiation |
| Recombinant albumin technology |
Moderate to high |
Relevant to non-plasma supply strategies |
| Trademarks and distribution |
Moderate |
Important in hospital procurement |
| Clinical method-of-use claims |
Moderate |
Relevant to long-term cirrhosis and combination therapy |
Manufacturing is the principal barrier to entry. A competitor needs qualified plasma, validated processes, licensed facilities, pharmacovigilance systems and commercial distribution. Patent expiration alone would not create immediate low-cost entry.
What generic and biosimilar launch scenarios exist?
Scenario 1: Additional plasma-derived suppliers
This is the most realistic near-term entry route. A manufacturer with existing fractionation infrastructure can add albumin capacity or enter a new region through local licensing.
Expected impact: Moderate price pressure, especially in tenders; limited disruption in highly regulated markets.
Scenario 2: Follow-on biologic or biosimilar albumin
A follow-on product could compete on price, supply reliability or concentration. Regulatory requirements would remain substantial because albumin is a complex biological product with batch-to-batch attributes tied to plasma and purification.
Expected impact: Potentially significant in price-sensitive markets, but adoption would depend on physician confidence and procurement policy.
Scenario 3: Recombinant human serum albumin
Recombinant albumin could reduce dependence on plasma and improve supply predictability. The principal challenges are production cost, scale, glycosylation and structural comparability, formulation performance and regulatory acceptance.
Expected impact: Long-term strategic threat to plasma-derived suppliers if cost parity and clinical comparability are achieved.
Scenario 4: Albumin-sparing clinical protocols
Hospitals may reduce use through more restrictive guidelines, crystalloid-first resuscitation, enhanced blood-management protocols and targeted use in cirrhosis.
Expected impact: Negative for indiscriminate ICU demand; limited effect on established paracentesis and hepatorenal syndrome use.
What competitive risks affect human albumin?
The main risks are operational rather than patent-driven.
| Risk |
Effect on market |
| Plasma shortages |
Supply interruption and higher acquisition cost |
| Regulatory action |
Product recall, license restrictions or manufacturing delays |
| Clinical trial failures |
Reduced use in broad ICU populations |
| Tender price compression |
Lower gross margins |
| Recombinant albumin |
Potential long-term displacement of plasma-derived supply |
| Local manufacturing mandates |
Reduced access to imported products |
| Hospital budget controls |
Greater substitution with crystalloids |
| Concentration-specific shortages |
Shifts in demand among 5%, 20% and 25% products |
Clinical demand should remain strongest in cirrhosis-related indications, therapeutic plasma exchange, selected surgical settings and specialized critical-care protocols. Routine use for hypoalbuminemia alone is less defensible clinically and commercially.
What is the outlook for human albumin through 2030?
The base-case outlook is steady market expansion with regional divergence.
North America and Western Europe are likely to remain high-value markets with sophisticated hospital procurement and established plasma supply. China and other Asia-Pacific markets are expected to deliver the strongest volume growth, although local manufacturing and pricing controls may limit multinational margins.
The most attractive development areas are:
- Long-term albumin in carefully selected cirrhosis populations
- Albumin combined with vasoconstrictors in hepatorenal syndrome
- Biomarker-guided administration
- Lower-volume, high-concentration formulations
- Recombinant albumin
- Albumin-based drug delivery
- Improved plasma utilization and fractionation yield
The largest downside risk is broad evidence-based restriction of albumin use outside established indications. The largest upside risk is a validated outpatient cirrhosis treatment model that expands dosing duration and reimbursement.
Key Takeaways
- Human albumin is a mature plasma-derived biologic with a global market estimated at approximately $5 billion-$7 billion in the early 2020s.
- Market forecasts generally support mid-single-digit growth through 2030.
- Grifols, CSL Behring, Takeda, Octapharma and Chinese manufacturers are major competitors.
- ANSWER supports long-term albumin in selected decompensated cirrhosis patients, while ATTIRE does not support routine targeted albumin for all hospitalized cirrhosis patients.
- Albumin has not demonstrated a broad mortality advantage over crystalloids in unselected critical-care populations.
- Orange Book and Paragraph IV mechanisms are generally not the principal basis for albumin competition.
- Manufacturing, plasma supply, viral-clearance validation and regulatory licensing are more important barriers than core composition patents.
- Recombinant albumin is the principal long-term technology capable of changing the supply structure.
- Generic entry is more likely through additional licensed biologics and regional plasma-derived suppliers than through conventional small-molecule generics.
- Revenue growth should be strongest in Asia-Pacific and in specialized cirrhosis, plasma-exchange and hospital applications.
FAQs
Is human albumin a biologic or a generic drug?
Human albumin is a plasma-derived biologic. It is not typically approved and commercialized through the conventional small-molecule generic pathway.
Does human albumin have biosimilars?
Human albumin has limited follow-on competition compared with insulin and monoclonal antibodies. The principal barriers are product characterization, plasma or recombinant production, viral safety and manufacturing consistency.
Is albumin recommended for low serum albumin alone?
Low serum albumin alone does not establish a universal indication for albumin infusion. Treatment depends on the underlying disease, volume status, renal function, cirrhosis complications and clinical objective.
Which albumin concentration is most commonly used?
Five-percent albumin is commonly used for plasma-volume expansion. Twenty-percent and 25% solutions are used when a higher oncotic concentration and lower infused volume are preferred.
Can recombinant albumin replace plasma-derived albumin?
Recombinant albumin could reduce plasma dependence, but commercial replacement requires competitive cost, manufacturing scale, structural comparability, regulatory approval and acceptance in hospital protocols.
References
-
Biggins, S. W., Angeli, P., Garcia-Tsao, G., Ginès, P., Ling, S. C., Nadim, M. K., Wong, F., & Kim, W. R. (2021). Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome. Hepatology, 74(2), 1014-1048.
-
Caironi, P., Tognoni, G., Masson, S., Fumagalli, R., Pesenti, A., Romero, M., et al. (2014). Albumin replacement in patients with severe sepsis or septic shock. New England Journal of Medicine, 370(15), 1412-1421.
-
Caraceni, P., Riggio, O., Angeli, P., Alessandria, C., Fiore, P., Marzano, A., et al. (2018). Long-term albumin administration in decompensated cirrhosis. The Lancet, 391(10138), 2417-2429.
-
China, L., Freemantle, N., Forrest, E., Kallis, Y., Ryder, S. D., Wright, G., et al. (2021). Targeted albumin therapy in patients with cirrhosis and ascites. New England Journal of Medicine, 384(9), 808-817.
-
European Association for the Study of the Liver. (2018). EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology, 69(2), 406-460.
-
Finfer, S., Bellomo, R., Boyce, N., French, J., Myburgh, J., Norton, R., & SAFE Study Investigators. (2004). A comparison of albumin and saline for fluid resuscitation in the intensive care unit. New England Journal of Medicine, 350(22), 2247-2256.
-
U.S. Food and Drug Administration. (2023). Biological product and drug product labeling for human albumin products. FDA.
-
Sharma, B., George, J., Sinha, S., et al. (2021). Albumin versus saline in cirrhosis with sepsis-induced hypotension. Hepatology, 74(4), 1946-1958.
